A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors
文献类型：期刊论文
| 作者 | Ren, Peng-xuan1,2; Shang, Wei-juan3; Yin, Wan-chao4; Ge, Huan5; Wang, Lin1,2; Zhang, Xiang-lei1,2; Li, Bing-qian1,2,6; Li, Hong-lin5; Xu, Ye-chun4,7 ; Xu, Eric H.4,7
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2021-04-27 |
| 页码 | 11 |
| 关键词 | SARS-CoV-2 inhibitors RdRp host ribosome Virus RNA |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-021-00668-7 |
| 通讯作者 | Zhu, Li-li(zhulfl@ecust.edu.cn) ; Zhang, Lei-ke(zhangleike@wh.iov.cn) ; Bai, Fang(baifang@shanghaitech.edu.cn) |
| 英文摘要 | The COVID-19, caused by SARS-CoV-2, is threatening public health, and there is no effective treatment. In this study, we have implemented a multi-targeted anti-viral drug design strategy to discover highly potent SARS-CoV-2 inhibitors, which simultaneously act on the host ribosome, viral RNA as well as RNA-dependent RNA polymerases, and nucleocapsid protein of the virus, to impair viral translation, frameshifting, replication, and assembly. Driven by this strategy, three alkaloids, including lycorine, emetine, and cephaeline, were discovered to inhibit SARS-CoV-2 with EC50 values of low nanomolar levels potently. The findings in this work demonstrate the feasibility of this multi-targeting drug design strategy and provide a rationale for designing more potent anti-virus drugs. |
| WOS关键词 | STRUCTURAL BASIS ; SARS-CORONAVIRUS ; REPLICATION ; SARS-COV-2 ; MECHANISMS ; LYCORINE ; PROTEIN ; IDENTIFICATION ; REMDESIVIR ; COVID-19 |
| 资助项目 | Science and Technology Commission of Shanghai Municipality[20431900102] ; Science and Technology Commission of Shanghai Municipality[20431900100] ; Science and Technology Commission of Shanghai Municipality[20430780300] ; Shanghai Science and Technology Development Funds[20QA1406400] ; Youth Innovation Promotion Association CAS[2018367] ; National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China[2018ZX09711002] ; National Natural Science Foundation of China[82003654] ; ShanghaiTech University |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000644822100001 |
| 出版者 | NATURE PUBLISHING GROUP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/296638]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Zhu, Li-li; Zhang, Lei-ke; Bai, Fang |
| 作者单位 | 1.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China 2.ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China 3.Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China 5.East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab Drug Design, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China 6.Imperial Coll London, Dept Chem, London, England 7.Univ Chinese Acad Sci, Beijing 100049, Peoples R China |
| 推荐引用方式 GB/T 7714 | Ren, Peng-xuan,Shang, Wei-juan,Yin, Wan-chao,et al. A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors[J]. ACTA PHARMACOLOGICA SINICA,2021:11. |
| APA | Ren, Peng-xuan.,Shang, Wei-juan.,Yin, Wan-chao.,Ge, Huan.,Wang, Lin.,...&Bai, Fang.(2021).A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors.ACTA PHARMACOLOGICA SINICA,11. |
| MLA | Ren, Peng-xuan,et al."A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors".ACTA PHARMACOLOGICA SINICA (2021):11. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。